Kenvue (NYSE:KVUE) Issues Quarterly Earnings Results, Meets Expectations

Kenvue (NYSE:KVUE) issued its quarterly earnings data on Friday. The company reported $0.29 EPS for the quarter, hitting the consensus estimate of $0.29, FiscalAI reports. The business had revenue of $3.89 billion for the quarter, compared to the consensus estimate of $3.86 billion. Kenvue had a return on equity of 21.22% and a net margin of 10.76%. The firm’s revenue was up 3.2% compared to the same quarter last year. During the same quarter last year, the business posted $0.28 EPS.

Kenvue Price Performance

KVUE stock opened at $19.26 on Friday. The stock has a 50-day moving average price of $18.40 and a two-hundred day moving average price of $18.19. The stock has a market cap of $36.99 billion, a PE ratio of 21.89, a price-to-earnings-growth ratio of 1.77 and a beta of 0.48. The company has a current ratio of 1.01, a quick ratio of 0.71 and a debt-to-equity ratio of 0.67. Kenvue has a 1 year low of $14.06 and a 1 year high of $20.13.

Kenvue Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, October 2nd. Investors of record on Monday, September 21st were paid a $0.21 dividend. The ex-dividend date of this dividend was Monday, September 21st. This represents a $0.84 dividend on an annualized basis and a yield of 4.4%. Kenvue’s dividend payout ratio is presently 96.55%.

Trending Headlines about Kenvue

Here are the key news stories impacting Kenvue this week:

• Positive Sentiment: Revenue increased 3.2% year over year to $3.89 billion, exceeding the roughly $3.86 billion consensus estimate. Management cited continued growth in Self Care and Essential Health, productivity initiatives, margin expansion and strong cash generation. Kenvue Reports Third Quarter 2026 Results
• Positive Sentiment: Reported earnings were $0.29 per share, up from $0.28 a year earlier. Zacks characterized the result as slightly ahead of its $0.28 consensus estimate, while other coverage said profit fell short of expectations, suggesting the market is focused on the exact earnings measure and guidance. Kenvue Surpasses Q3 Earnings Estimates
• Positive Sentiment: The quarterly performance represents Kenvue’s fourth consecutive quarter of net and organic sales growth, supporting management’s efforts to rebuild momentum across its consumer-health brands. Kenvue Profit, Revenue Rise as Turnaround Efforts Continue
• Neutral Sentiment: Kenvue’s results arrive as its approximately $40 billion acquisition by Kimberly-Clark approaches closing. The deal may provide strategic support, but investors remain focused on execution, integration and the turnaround’s durability. Kenvue Q3 2026 Revenue Beats as Kimberly-Clark Deal Nears Close
• Negative Sentiment: The conflicting earnings headlines indicate that profit performance did not clearly exceed investor expectations, even though revenue beat forecasts. Earlier concerns about inflation and cautious consumer spending also remain potential pressures on margins and demand. Kenvue Misses Third-Quarter Profit Expectations

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the company. HSBC lowered their price target on Kenvue from $20.00 to $19.00 and set a “hold” rating for the company in a report on Monday, August 10th. Weiss Ratings reiterated a “hold (c)” rating on shares of Kenvue in a research report on Friday, September 11th. Barclays boosted their price objective on Kenvue from $18.00 to $19.00 and gave the company an “equal weight” rating in a research report on Tuesday, July 21st. UBS Group lowered their target price on Kenvue from $20.00 to $19.00 and set a “neutral” rating for the company in a research note on Tuesday, August 11th. Finally, Zacks Research downgraded shares of Kenvue from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 7th. Thirteen analysts have rated the stock with a Hold rating. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $19.33.

About Kenvue

Kenvue Inc is a consumer health company that develops, markets and sells products designed to support everyday health and personal care. Its portfolio spans over-the-counter medicines, skin health and beauty, and essential health products, serving consumers through retail, e-commerce and other distribution channels.

The company’s brands include Tylenol, Motrin, Zyrtec and Benadryl in self-care; Neutrogena, Aveeno and Clean & Clear in skin health and beauty; and Listerine, Johnson’s and OGX in oral care, baby care and hair care.